
ASH 2023: Durable Responses Observed with Valemetostat Improved Outcomes in Second-Line Treatment of Large B-Cell Lymphoma in the Era of CAR T-Cell Therapies
ASH 2023: Durable Responses Observed with Valemetostat Improved Outcomes in Second-Line Treatment of Large B-Cell Lymphoma in the Era of CAR T-Cell Therapies The treatment landscape of large B-cell lymphomas (LBCL) has changed dramatically in recent years, driven in part…